Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Teva Pharmaceutical (Four Oncology R&D Assets)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Four oncology development programs of Teva Pharmaceutical Industries. The business assets are CEP-32496, a potent small molecule inhibitor of BRAF, EGFR and RET, CEP-40783, a potent, highly selective, pseudo-irreversible inhibitor of AXL and cMET, CEP-40125, a nanoformulation of a modified bendamustine with potential activity in solid tumors and TEV-44229, a potent, selective inhibitor of the atypical kinase PKCiota that is in preclinical studies.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • San Diego, CA 92121
  • United States

Teva Pharmaceutical (Four Oncology R&D Assets) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.

Request full access to PitchBook

Teva Pharmaceutical (Four Oncology R&D Assets) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.

Request full access to PitchBook